When To Buy The Dip? Goldman's Meeting With Novo Nordisk Execs Offers Clues

Novo Nordisk shares remain locked in an eight-month downtrend, shedding nearly half of its market capitalization as competitive pressures mount. The Danish pharmaceutical giant is losing ground to Eli Lilly's Zepbound. At the same time, its next-generation anti-obesity drug, CagriSema, recently fell short of Goldman's expectations